HIBCH and colorectal cancer: In models of colorectal cancer, disruption of valine catabolism via the inhibition of HIBCH reduces TCA metabolite levels, inhibits tumour xenograft growth and reduces the occurrence of drug-acquired resistance to bevacizumab [18].